Consequences of inhibition of plasma carboxypeptidase B on in vivo thrombolysis, thrombosis and hemostasis
- 1 September 2000
- journal article
- Published by Elsevier in Fibrinolysis and Proteolysis
- Vol. 14 (5), 305-314
- https://doi.org/10.1054/fipr.2000.0087
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- TAFIFibrinolysis and Proteolysis, 1999
- Both Cellular and Soluble Forms of Thrombomodulin Inhibit Fibrinolysis by Potentiating the Activation of Thrombin-activable Fibrinolysis InhibitorJournal of Biological Chemistry, 1998
- Thrombin, Thrombomodulin and TAFI in the Molecular Link Between Coagulation and FibrinolysisThrombosis and Haemostasis, 1997
- TAFI, or Plasma Procarboxypeptidase B, Couples the Coagulation and Fibrinolytic Cascades through the Thrombin-Thrombomodulin ComplexPublished by Elsevier ,1996
- Inducible Carboxypeptidase ActivityCirculation, 1996
- Plasma carboxypeptidases as regulators of the plasminogen system.Journal of Clinical Investigation, 1995
- Purification and Characterization of TAFI, a Thrombin-activable Fibrinolysis InhibitorJournal of Biological Chemistry, 1995
- Activation and Characterization of Procarboxypeptidase B from Human PlasmaBiochemistry, 1995
- Purification and characterization of a new arginine carboxypeptidase in human serumBiochimica et Biophysica Acta (BBA) - General Subjects, 1990
- An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunitsBiochemical and Biophysical Research Communications, 1989